A recent clinical study, known as EVITA, has shed new light on the potential therapeutic benefits of oral vitamin C for individuals suffering from pre-cancerous blood conditions and specific low-risk blood cancers. This investigation explored how vitamin C, a known activator of TET enzymes crucial for gene regulation, might influence disease progression and patient outcomes. The findings, published in the journal CANCER, provide a foundation for future research into vitamin C's role in intercepting leukemia development.
The EVITA trial, a phase 2, randomized, double-blind, and placebo-controlled study, involved 109 patients across Denmark and the United States. These participants were diagnosed with either a blood disorder that carries a risk of evolving into cancer or an early-stage, low-risk blood malignancy. For a duration of 12 months, 55 patients received a daily oral supplement of 1,000 mg of vitamin C, while the remaining 54 were given a placebo.
Although the trial's main objective—to reduce the growth rate of pre-cancerous or cancerous cells—did not show a significant difference between the two groups, other notable effects were observed. Participants receiving vitamin C displayed beneficial alterations in inflammatory signaling pathways, which are often associated with improved health outcomes. Furthermore, certain health issues such as anemia, pneumonia, acute aseptic arthritis, and internal bleeding occurred less frequently in the vitamin C group compared to the placebo group. Conversely, gastrointestinal problems were more prevalent among those taking vitamin C.
Following a median observation period of 33.6 months, the study recorded 35 deaths, with 24 in the placebo group and 11 in the vitamin C group. An initial analysis of these mortality data suggested that individuals in the vitamin C group might have a better chance of survival during the follow-up period. This encouraging signal underscores the importance of conducting a larger-scale phase 3 clinical trial to confirm these preliminary observations.
Dr. Peter A. Jones, a co-senior author from Van Andel Institute and co-leader of the VAI–SU2C Epigenetics Dream Team, emphasized that the EVITA trial offers a compelling rationale to delve deeper into how vitamin C could positively impact patients with pre-cancerous or early-stage blood cancers. He expressed cautious optimism that these discoveries could eventually shape future strategies aimed at preventing leukemia progression. Dr. Kirsten Grønbæk, another co-senior author from Rigshospitalet, Copenhagen University Hospital, echoed this sentiment, highlighting the promising implications for individuals with these early blood disorders and the need for a more comprehensive study to provide conclusive answers.
In summary, the EVITA trial provides valuable insights into the multifaceted effects of vitamin C supplementation in managing pre-cancerous blood conditions. While further validation through larger studies is essential, the observed improvements in inflammatory markers and the potential survival benefit indicate a promising direction for future research in cancer interception and treatment.